Bhatt Deepak L, Hull Mark A, Song Mingyang, Van Hulle Carol, Carlsson Cindy, Chapman M John, Toth Peter P
Brigham and Women's Hospital, Heart & Vascular Center and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Division of Gastrointestinal and Surgical Sciences, Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, LS9 7TF, UK.
Eur Heart J Suppl. 2020 Oct 6;22(Suppl J):J54-J64. doi: 10.1093/eurheartj/suaa119. eCollection 2020 Oct.
The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being actively explored in clinical studies. These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer's disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.
REDUCE-IT试验表明，二十碳五烯酸乙酯（icosapent ethyl），即二十碳五烯酸（EPA）的乙酯，可在很大程度上降低高危人群的心血管事件。虽然这种化合物的心血管保护特性现已得到证实，但临床研究正在积极探索其他几种潜在用途。这些研究领域包括癌症、炎症性肠病、感染、阿尔茨海默病、痴呆症和抑郁症。未来十年有望加深我们对EPA除降低心血管风险之外可能带来的有益影响的理解。
